keyword
MENU ▼
Read by QxMD icon Read
search

mrsa bacteremia treatment

keyword
https://www.readbyqxmd.com/read/29298323/implementation-of-global-antimicrobial-resistance-surveillance-system-glass-in-patients-with-bacteremia
#1
Rujipas Sirijatuphat, Kantarida Sripanidkulchai, Adhiratha Boonyasiri, Pinyo Rattanaumpawan, Orawan Supapueng, Pattarachai Kiratisin, Visanu Thamlikitkul
The global antimicrobial resistance surveillance system (GLASS) was launched by the World Health Organization (WHO) in 2015. GLASS is a surveillance system for clinical specimens that are sent to microbiology laboratory for clinical purposes. The unique feature of GLASS is that clinical data is combined with microbiological data, and deduplication of the microbiological results is performed. The objective of the study was to determine feasibility and benefit of GLASS for surveillance of blood culture specimens...
2018: PloS One
https://www.readbyqxmd.com/read/29235661/association-of-higher-daptomycin-dose-%C3%A2-7-mg-kg-with-improved-survival-in-patients-with-methicillin-resistant-staphylococcus-aureus-bacteremia
#2
Tristan T Timbrook, Aisling R Caffrey, Megan K Luther, Vrishali Lopes, Kerry L LaPlante
STUDY OBJECTIVE: Current guidelines recommend higher daptomycin doses than the daptomycin label dose of 6 mg/kg for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia; however, the evidence supporting this recommendation is from in vitro and cases series studies. The objective of this study was to evaluate the comparative effectiveness of the daptomycin label dose versus higher daptomycin doses in patients with MRSA bacteremia. DESIGN: Retrospective national cohort study...
December 13, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/29222405/multiple-weekly-dalbavancin-dosing-for-the-treatment-of-native-vertebral-osteomyelitis-caused-by-methicillin-resistant-staphylococcus-aureus-a-case-report
#3
Thamer A Almangour, Valerie Fletcher, Mohammed Alessa, Abdullah A Alhifany, Deanne Tabb
BACKGROUND Native vertebral osteomyelitis (NVO) is a common form of hematogenous osteomyelitis, with Staphylococcus aureus (S. aureus) being the most commonly isolated organism. Dalbavancin is approved by the US Food and Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and has a sufficiently promising pharmacokinetic and pharmacodynamic profile to be considered for the treatment of vertebral osteomyelitis. We describe here what is probably the first reported case of using multiple weekly dalbavancin to treat a complicated methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and vertebral osteomyelitis...
December 9, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/29203479/host-pathogen-treatment-triad-host-factors-matter-most-in-mrsa-bacteremia-outcomes
#4
M Cristina Vazquez Guillamet, Rodrigo Vazquez, Benjamin Deaton, Jenny Shroba, Laia Vazquez, Renee-Claude Mercier
Background: Previous studies have separately emphasized the importance of host, pathogen and treatment characteristics in determining short term or in-hospital mortality for patients with methicillin resistant Staphylococcus aureus (MRSA) bloodstream infections. Less is known about the relative importance of these factors and their interaction in determining short, medium and long-term mortality.Methods: This is an observational cohort study where all patients admitted to University of New Mexico Health Sciences Center (UNM HSC) between July 2002 and August 2013 with MRSA positive blood cultures were recorded...
December 4, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29180523/efficacy-of-novel-anti-staphylococcal-ectolysin-p128-in-a-rat-model-of-methicillin-resistant-staphylococcus-aureus-mrsa-bacteremia
#5
Shankaramurthy Channabasappa, Murali Durgaiah, Ravisha Chikkamadaiah, Senthil Kumar, Amruta Joshi, Bharathi Sriram
Staphylococcus aureus (S.aureus) causes systemic infections with high morbidity and mortality and emergence of drug resistance strains are a rapidly growing clinical concerns. Novel therapeutic agents are required to tackle S.aureus infections. P128 is a bacteriophage-derived chimeric ectolysin with potent and rapid bactericidal activity on S. aureus In the current study, efficacy of P128 was evaluated in a newly-developed rat model of S. aureus bacteremia. Prior to in vivo testing, P128 was shown to be stable in whole blood by incubation in rat blood for up to 6 hrs and testing of its bactericidal activity against MRSA isolate USA 300...
November 27, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29169153/optimal-trough-concentration-of-teicoplanin-in-febrile-neutropenic-patients-with-hematological-malignancy
#6
Yuhki Sato, Kazufumi Hiramatsu, Yosuke Suzuki, Ryota Tanaka, Tetsuya Kaneko, Ko Nonoshita, Masao Ogata, Jun-Ichi Kadota, Hiroki Itoh
BACKGROUND: Teicoplanin is a glycopeptide antibiotic currently used for the treatment of methicillin-resistant Staphylococcus aureus. The need for therapeutic drug monitoring of teicoplanin has been increasingly highlighted as important. It is generally accepted that whereas a plasma trough concentration (Cmin) of ≥10 mg/L is appropriate for the majority of infections, it should exceed 20 mg/L for severe infections. The target Cmin of teicoplanin in patients with febrile neutropenia (FN) has not been reported...
November 24, 2017: Chemotherapy
https://www.readbyqxmd.com/read/29163457/the-agr-quorum-sensing-system-represses-persister-formation-through-regulation-of-phenol-soluble-modulins-in-staphylococcus-aureus
#7
Tao Xu, Xu-Yang Wang, Peng Cui, Yu-Meng Zhang, Wen-Hong Zhang, Ying Zhang
The opportunistic pathogen Staphylococcus aureus has become an increasing threat to public health. While the Agr quorum sensing (QS) system is a master regulator of S. aureus virulence, its dysfunction has been frequently reported to promote bacteremia and mortality in clinical infections. Here we show that the Agr system is involved in persister formation in S. aureus. Mutation of either agrCA or agrD but not RNAIII resulted in increased persister formation of stationary phase cultures. RNA-seq analysis showed that in stationary phase AgrCA/AgrD and RNAIII mutants showed consistent up-regulation of virulence associated genes (lip and splE, etc...
2017: Frontiers in Microbiology
https://www.readbyqxmd.com/read/29153470/impact-of-a-pharmacist-driven-care-package-on-staphylococcus-aureus-bacteremia-management-in-a-large-community-healthcare-network-a-propensity-score-matched-quasi-experimental-study
#8
Jordan R Smith, Jeremy J Frens, Cynthia B Snider, Kimberly C Claeys
OBJECTIVES: Staphylococcus aureus bacteremia (SAB) is an important cause of morbidity and mortality. Suboptimal treatment has been associated with poor patient outcomes. Our antimicrobial stewardship program (ASP) evaluated SAB management based on predefined performance measures both prior to and after instituting a "care package" intervention led by clinical pharmacists and infectious diseases physicians. The primary outcome included a 4-point "optimal care score" (OCS) consisting of targeted antibiotic therapy within 24hours, repeating blood cultures, antibiotic duration assessment, and appropriate duration of therapy...
October 7, 2017: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/29137718/telavancin-for-the-treatment-of-methicillin-resistant-staphylococcus-aureus-bone-and-joint-infections
#9
Julie Harting, Francisco Fernandez, Rob Kelley, Tim Wiemken, Paula Peyrani, Julio Ramirez
This retrospective, case series describes our experience with the use of telavancin in patients with methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis and prosthetic joint infection. The primary objectives were clinical outcomes and adverse events (AEs), and a secondary outcome described microbiological susceptibility. Fourteen patients were enrolled. Median duration of therapy was 58 days, and four patients had concurrent bacteremia. End-of-treatment outcomes were available in 78% of patients, with a clinical success rate of 91%...
December 2017: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/29133561/outcomes-of-vancomycin-plus-a-%C3%AE-lactam-versus-vancomycin-only-for-the-treatment-of-methicillin-resistant-staphylococcus-aureus-bacteremia
#10
James Truong, John J Veillette, Steve C Forland
The objective of this retrospective study was to compare the rates of treatment failure, which was a composite of clinical and microbiologic failure, of patients receiving vancomycin and a β-lactam to those receiving vancomycin only for MRSA bacteremia. Patients 16 to 89 years of age with MRSA bacteremia admitted to a university-affiliated hospital from January 1(st), 2014 to December 31(st), 2016 were screened for study inclusion. Patients were eligible if they received >48 hours of vancomycin and a β-lactam (combination group) or vancomycin only (standard group) within 48 hours following bacteremia onset...
November 13, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29038267/a-retrospective-analysis-of-treatment-and-clinical-outcomes-among-patients-with-methicillin-susceptible-staphylococcus-aureus-bloodstream-isolates-possessing-detectable-meca-by-a-commercial-pcr-assay-compared-to-patients-with-methicillin-resistant-staphylococcus
#11
Dylan Jones, Ramy H Elshaboury, Erik Munson, Thomas J Dilworth
mecA-positive Staphylococcus aureus isolates phenotypically susceptible to cefoxitin (mecA-MSSA) have been identified. We describe treatment and outcomes among patients with mecA-MSSA bloodstream infections (BSI) and MRSA BSI patients matched 1:1 on age, BSI origin and BSI type (n=17 per group). Compared to MRSA BSI patients, mecA-MSSA BSI patients more often experienced clinical failure (58.8% and 11.8%, p=0.010), driven largely by persistent bacteremia (35.3% and 11.8%). mecA-MSSA BSI patients may be at higher risk for poor clinical outcomes...
October 16, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28954388/pretreatment-of-pam3csk4-attenuates-inflammatory-responses-caused-by-systemic-infection-of-methicillin-resistant-staphylococcus-aureus-in-mice
#12
Zhaoxia Huang, Xiayu Yi, Yiguo Chen, Xiaorui Hou, Xiangyu Wang, Ping Zhu, Kangmin Zhao, Shuangshuang Wu, Ning Fu, Beiyi Liu
Pam3CSK4 is a synthetic tripalmitoylated lipopeptide that acts as a ligand of TLR1/TLR2 by mimicking the acetylated amino terminus of bacterial lipoproteins. Here we found that pretreatment of Pam3CSK4 protected mice from systemic infection of methicillin-resistant Staphylococcus aureus (MRSA), and enhanced the bacterial clearance in bacteremia model. Pro-inflammatory cytokines, such as TNF-α, IL-6, MCP-1 and IFN-γ were significantly decreased in serum from Pam3CSK4-treated mice. Besides, upon PamCSK4 treatment, the TLR2 expression was down-regulated, IRAK1 phosphorylation was inhibited, and the expression of IRAK-M and Tollip, two negative regulators of NF-κB pathway, was up-regulated...
November 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28949410/early-administration-of-adjuvant-%C3%AE-lactam-therapy-in-combination-with-vancomycin-among-patients-with-methicillin-resistant-staphylococcus-aureus-bloodstream-infection-a-retrospective-multicenter-analysis
#13
Anthony M Casapao, David M Jacobs, Dana R Bowers, Nicholas D Beyda, Thomas J Dilworth
STUDY OBJECTIVE: To determine whether early administration of adjuvant β-lactam in combination with vancomycin (COMBO) affects clinical outcomes compared to standard vancomycin therapy alone (STAN) among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection. DESIGN: Retrospective, multicenter cohort study. SETTING: Five academic or community hospitals throughout the United States. PATIENTS: Adults with MRSA bloodstream infections treated with vancomycin (≥ 72 hrs) with or without an intravenous β-lactam (≥ 48 hrs) initiated within 24 hours of initiating vancomycin...
November 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28943633/vancomycin-induced-leukocytoclastic-vasculitis-and-acute-renal-failure-due-to-tubulointerstitial-nephritis
#14
Chandra Shekar Pingili, Emmanuel E Okon
BACKGROUND Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and sepsis are commonly treated with intravenous vancomycin. However, vancomycin treatment is associated adverse reactions, including skin rashes and nephrotoxicity. We present a case of acute renal failure due to acute tubulointerstitial nephritis associated with a diffuse leukocytoclastic vasculitic skin eruption following intravenous vancomycin treatment. CASE REPORT A 79-year-old Caucasian male patient was treated with intravenous vancomycin for MRSA bacteremia...
September 25, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28900682/treatment-of-staphylococcus-aureus-infections
#15
Michael Z David, Robert S Daum
Staphylococcus aureus, although generally identified as a commensal, is also a common cause of human bacterial infections, including of the skin and other soft tissues, bones, bloodstream, and respiratory tract. The history of S. aureus treatment is marked by the development of resistance to each new class of antistaphylococcal antimicrobial drugs, including the penicillins, sulfonamides, tetracyclines, glycopeptides, and others, complicating therapy. S. aureus isolates identified in the 1960s were sometimes resistant to methicillin, a ß-lactam antimicrobial active initially against a majority S...
September 13, 2017: Current Topics in Microbiology and Immunology
https://www.readbyqxmd.com/read/28818549/integration-of-dpc-and-clinical-microbiological-data-in-japan-reveals-importance-of-confirming-a-negative-follow-up-blood-culture-in-patients-with-mrsa-bacteremia
#16
Naoki Miyamoto, Koji Yahara, Rie Horita, Tomomi Yano, Naotaka Tashiro, Daiichi Morii, Atsuko Tsutsui, Kenichiro Yaita, Keigo Shibayama, Hiroshi Watanabe
Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is one of the commonest and most life-threatening of all infectious diseases. The morbidity and mortality rates associated with MRSA bacteremia are higher than those associated with bacteremia caused by other pathogens. A common guideline in MRSA bacteremia treatment is to confirm bacteremia clearance through additional blood cultures 2-4 days after initial positive cultures and as needed thereafter. However, no study has presented statistical evidence of how and to what extent confirming a negative follow-up blood culture impacts clinical outcome...
October 2017: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://www.readbyqxmd.com/read/28807042/incidence-prevalence-and-management-of-mrsa-bacteremia-across-patient-populations-a-review-of-recent-developments-in-mrsa-management-and-treatment
#17
REVIEW
Ali Hassoun, Peter K Linden, Bruce Friedman
Methicillin-resistant Staphylococcus aureus (MRSA) infection is still a major global healthcare problem. Of concern is S. aureus bacteremia, which exhibits high rates of morbidity and mortality and can cause metastatic or complicated infections such as infective endocarditis or sepsis. MRSA is responsible for most global S. aureus bacteremia cases, and compared with methicillin-sensitive S. aureus, MRSA infection is associated with poorer clinical outcomes. S. aureus virulence is affected by the unique combination of toxin and immune-modulatory gene products, which may differ by geographic location and healthcare- or community-associated acquisition...
August 14, 2017: Critical Care: the Official Journal of the Critical Care Forum
https://www.readbyqxmd.com/read/28760895/a-prospective-cohort-multicenter-study-of-molecular-epidemiology-and-phylogenomics-of-staphylococcus-aureus-bacteremia-in-nine-latin-american-countries
#18
Cesar A Arias, Jinnethe Reyes, Lina Paola Carvajal, Sandra Rincon, Lorena Diaz, Diana Panesso, Gabriel Ibarra, Rafael Rios, Jose M Munita, Mauro J Salles, Carlos Alvarez-Moreno, Jaime Labarca, Coralith Garcia, Carlos M Luna, Carlos Mejia-Villatoro, Jeannete Zurita, Manuel Guzman-Blanco, Eduardo Rodriguez-Noriega, Apurva Narechania, Laura J Rojas, Paul J Planet, George M Weinstock, Eduardo Gotuzzo, Carlos Seas
Staphylococcus aureus is an important pathogen causing a spectrum of diseases ranging from mild skin and soft tissue infections to life-threatening conditions. Bloodstream infections are particularly important, and the treatment approach is complicated by the presence of methicillin-resistant S. aureus (MRSA) isolates. The emergence of new genetic lineages of MRSA has occurred in Latin America (LA) with the rise and dissemination of the community-associated USA300 Latin American variant (USA300-LV). Here, we prospectively characterized bloodstream MRSA recovered from selected hospitals in 9 Latin American countries...
October 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28702467/ceftaroline-for-severe-methicillin-resistant-staphylococcus-aureus-infections-a-systematic-review
#19
REVIEW
Reese A Cosimi, Nahal Beik, David W Kubiak, Jennifer A Johnson
Ceftaroline is approved by the Food and Drug Administration for acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia, including cases with concurrent bacteremia. Use for serious methicillin-resistant Staphylococcus aureus (MRSA) infections has risen for a multitude of reasons. The aim of this article is to review the literature evaluating clinical outcomes and safety of ceftaroline prescribed for serious MRSA infections. We conducted a literature search in Ovid (Medline) and PubMed for reputable case reports, clinical trials, and reviews focusing on the use of ceftaroline for treatment of MRSA infections...
2017: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/28634536/telavancin-a-novel-semisynthetic-lipoglycopeptide-agent-to-counter-the-challenge-of-resistant-gram-positive-pathogens
#20
REVIEW
Biswadeep Das, Chayna Sarkar, Debasmita Das, Amit Gupta, Arnav Kalra, Shubham Sahni
Telavancin (TD-6424), a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration (USFDA) had approved telavancin in 2009 for the treatment of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria, including MRSA (S. aureus, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus anginosus group, or Enterococcus faecalis)...
March 2017: Therapeutic Advances in Infectious Disease
keyword
keyword
105562
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"